The human milk oligosaccharides market is anticipated to expand at a CAGR of 22.7% during the anticipated time frame. According to projections, the market would be worth US$ 1,539.21Mn by 2032, up from US$ 199.0Mn in 2022.
According to WHO, the total world population is estimated to increase by approximately one billion in the next 10 years and will reach 9.5 billion by 2050. Incidentally, demand has been relatively higher to the supply of infant nutrition products. Meanwhile, sales of infant formula are also surging in some of the Asian countries such as China and India, promoting the consumption of HMO alike. Future Market Insights’ latest report reveals that the global human milk oligosaccharides market is set to surpass a valuation of US$ 76 Mn, registering a CAGR of 22.7% between 2022 and 2032. This growth will be primarily orchestrated by the increasing application of HMO in infant nutrition products.
Request for Sample Report @
https://www.futuremarketinsights.com/reports/sample/rep-gb-4252
The human milk oligosaccharides market in Europe is expected to increase significantly in 2017 and beyond. By the end of 2027, Europe is expected to account for more than 49% of the global market in terms of value. Manufacturers in Europe are applying for regulatory permits and product safety certifications to use HMO in the preparation of newborn formulae. The HMO market in North America is presently valued at about US$ 6 Mn, ranking second only to Europe in terms of market size.
FMI’s report, titled “Human Milk Oligosaccharides Market Global Industry Analysis and Opportunity Assessment, 2017 – 2027” also cites that demand for HMO is gaining traction due to a positive perception of its prebiotic properties that help maintain a healthy immune system in infants. In addition, manufacturers are focusing on increasing their production capacities in order to enhance production of HMOs such as 2’-FL (2-fucosyllactose) that can be potentially used as an ingredient in functional food and beverages. zuChem Inc., Glycosyn LLC, Elicityl SA, Jennewein Biotechnologie GmbH, Glycom A/S, Dextra Laboratories Limited, Carbosynth Limited, Inbiose NV, ProZyme, Inc. are the leading companies operating in the global human milk oligosaccharides market.
Key Excerpts of the Report Include:
- Among product type, fucosyllactose HMO currently accounts for the largest value share of the market followed by sialyllactose HMO. However, the latter is expected to register a faster growth rate in terms of the market value over the forecast period.
- By 2017-end, US$ 5.5 Mn worth sialyllactose HMO is expected to be consumed globally.
- Increasing demand for functional food and beverage products is projected to further facilitate the growth of global human milk oligosaccharides market over the next couple of years.
Visit for Customization Before Purchasing @
https://www.futuremarketinsights.com/customization-available/rep-gb-
Market Segmentation
By Product Type
- Fucosyllactose
- LNT & LNnT
- Sialyllactose
By Region
- North America
- Europe
- Asia Pacific
About Us
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights Inc.
Christiana Corporate,
200 Continental Drive,
Suite 401, Newark,
Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse latest Market Reports: https://www.futuremarketinsights.com/reports
LinkedIn | Twitter | Blogs
